Reprogramming cell death: BCL2 family inhibition in hematological malignancies

Immunology Letters

Volumn 155, Issue 1-2, 2013, Pages 36-39

  Scarfò, Lydia ^a   Ghia, Paolo ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

BCL2 family; BH3 mimetics; Chronic lymphocytic leukemia apoptosis

Indexed keywords

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; ABT 199; ANTINEOPLASTIC AGENT; BENDAMUSTINE; CYCLOPHOSPHAMIDE; FLUDARABINE; ISOSORBIDE; NAVITOCLAX; OBATOCLAX; OBLIMERSEN; PROTEIN BCL 2; PROTEIN BCL XL; RITUXIMAB; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CELL DEATH; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; FEVER; GASTROINTESTINAL TOXICITY; HEMATOLOGIC MALIGNANCY; HUMAN; HYPOTENSION; LARGE CELL LYMPHOMA; MENTAL DISEASE; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN TARGETING; REVIEW; THROMBOCYTOPENIA; TUMOR LYSIS SYNDROME;

BCL2 FAMILY; BH3 MIMETICS; CHRONIC LYMPHOCYTIC LEUKEMIA APOPTOSIS;

ANIMALS; APOPTOSIS REGULATORY PROTEINS; BIOMIMETICS; CELL DEATH; CLINICAL TRIALS AS TOPIC; DNA, ANTISENSE; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HEMATOLOGIC NEOPLASMS; HUMANS; NUCLEAR REPROGRAMMING; PROTO-ONCOGENE PROTEINS C-BCL-2; PYRROLES; THIONUCLEOTIDES;

EID: 84887819279     PISSN: 01652478     EISSN: 18790542     Source Type: Journal    
DOI: 10.1016/j.imlet.2013.09.015     Document Type: Review

References (29)

1. Kelly P.N., Strasser A. The role of Bcl-2 and its pro-survival relatives in tumourigenesis and cancer therapy. Cell Death Differ 2011, 18:1414-1424.
2. Tsujimoto Y., Cossman J., Jaffe E., Croce C.M. Involvement of the bcl-2 gene in human follicular lymphoma. Science 1985, 228:1440-1443.
3. Reed J.C. Bcl-2-family proteins and hematologic malignancies: history and future prospects. Blood 2008, 111:3322-3330.
4. Ghia P., Boussiotis V.A., Schultze J.L., Cardoso A.A., Dorfman D.M., Gribben J.G., et al. Unbalanced expression of bcl-2 family proteins in follicular lymphoma: contribution of CD40 signaling in promoting survival. Blood 1998, 91:244-251.
5. Monni O., Joensuu H., Franssila K., Klefstrom J., Alitalo K., Knuutila S. BCL2 overexpression associated with chromosomal amplification in diffuse large B-cell lymphoma. Blood 1997, 90:1168-1174.
6. Hanada M., Delia D., Aiello A., Stadtmauer E., Reed J.C. BCL-2 gene hypomethylation and high-level expression in B-cell chronic lymphocytic leukemia. Blood 1993, 82:1820-1828.
7. Cimmino A., Calin G.A., Fabbri M., Iorio M.V., Ferracin M., Shimizu M., et al. miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci USA 2005, 102:13944-13949.
8. Pepper C., Lin T.T., Pratt G., Hewamana S., Brennan P., Hiller L., et al. Mcl-1 expression has in vitro and in vivo significance in chronic lymphocytic leukemia and is associated with other poor prognostic markers. Blood 2008, 112:3807-3817.
9. Kang M.H., Reynolds C.P. Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy. Clin Cancer Res 2009, 15:1126-1132.
10. Davids M.S., Letai A. Targeting the B-cell lymphoma/leukemia 2 family in cancer. J Clin Oncol 2012, 30:3127-3135.
11. Vogler M., Dinsdale D., Dyer M.J., Cohen G.M. Bcl-2 inhibitors: small molecules with a big impact on cancer therapy. Cell Death Differ 2009, 16:360-367.
12. Lessene G., Czabotar P.E., Colman P.M. BCL-2 family antagonists for cancer therapy. Nat Rev Drug Discov 2008, 7:989-1000.
13. Schena M., Gottardi D., Ghia P., Larsson L.G., Carlsson M., Nilsson K., et al. The role of Bcl-2 in the pathogenesis of B chronic lymphocytic leukemia. Leuk Lymphoma 1993, 11:173-179.
14. O'Brien S.M., Cunningham C.C., Golenkov A.K., Turkina A.G., Novick S.C., Rai K.R. Phase I to II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in patients with advanced chronic lymphocytic leukemia. J Clin Oncol 2005, 23:7697-7702.
15. O'Brien S., Moore J.O., Boyd T.E., Larratt L.M., Skotnicki A., Koziner B., et al. Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia. J Clin Oncol 2007, 25:1114-1120.
16. O'Brien S., Moore J.O., Boyd T.E., Larratt L.M., Skotnicki A.B., Koziner B., et al. 5-year survival in patients with relapsed or refractory chronic lymphocytic leukemia in a randomized, phase III trial of fludarabine plus cyclophosphamide with or without oblimersen. J Clin Oncol 2009, 27:5208-5212.
17. Ni Chonghaile T., Letai A. Mimicking the BH3 domain to kill cancer cells. Oncogene 2008, 27(Suppl 1):S149-S157.
18. Nguyen M., Marcellus R.C., Roulston A., Watson M., Serfass L., Murthy Madiraju S.R., et al. Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis. Proc Natl Acad Sci USA 2007, 104:19512-19517.
19. Konopleva M., Watt J., Contractor R., Tsao T., Harris D., Estrov Z., et al. Mechanisms of antileukemic activity of the novel Bcl-2 homology domain-3 mimetic GX15-070 (obatoclax). Cancer Res 2008, 68:3413-3420.
20. Brown J.R., Tesar B., Werner L., Mikler E., Reynolds H., Thompson C., et al. Obatoclax in combination with fludarabine and rituximab (FR) is well-tolerated and shows promising clinical activity in relapsed CLL/SLL. Blood 2011, 118:2865. abstr.
21. Castro J.E., Olivier L.J., Robier A.A., Danelle J., Carlos S.J., Bi-Ying Y., et al. A phase II, open label study of AT-101 in combination with rituximab in patients with relapsed or refractory chronic lymphocytic leukemia. Blood 2006, 108:2838. abstr.
22. Tse C., Shoemaker A.R., Adickes J., Anderson M.G., Chen J., Jin S., et al. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res 2008, 68:3421-3428.
23. Roberts A.W., Seymour J.F., Brown J.R., Wierda W.G., Kipps T.J., Khaw S.L., et al. Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease. J Clin Oncol 2012, 30:488-496.
24. Kipps T.J., Swinnen L.J., Wierda W.G., Jones J.A., Coutre S.E., Smith M.R., et al. Navitoclax (ABT-263) plus fludarabine/cyclophosphamide/rituximab (FCR) or bendamustine/rituximab (BR): a phase 1 study in patients with relapsed/refractory chronic lymphocytic leukemia (CLL). Blood 2011, 118:3904. abstr.
25. Vandenberg C.J., Cory S. ABT-199, a new Bcl-2-specific BH3 mimetic, has in vivo efficacy against aggressive Myc-driven mouse lymphomas without provoking thrombocytopenia. Blood 2013, 121:2285-2288.
26. Souers A.J., Leverson J.D., Boghaert E.R., Ackler S.L., Catron N.D., Chen J., et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med 2013, 19:202-208.
27. Davids M.S., Seymour J.F., Gerecitano J.F., Kahl B.S., Pagel J.M., Wierda W.G., et al. Updated results of a phase I first-in-human study of the BCL-2 inhibitor ABT-199 (GDC-0199) in patients with relapsed/refractory non-Hodgkin lymphoma (NHL). J Clin Oncol 2013, 31(suppl). (abstr 8520).
28. Seymour J.F., Davids M.S., Pagel J.M., Kahl B.S., Wierda W.G., Miller T.P., et al. Updated results of a phase I first-in-human study of the BCL-2 inhibitor ABT-199 (GDC-0199) in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL). J Clin Oncol 2013, 31(suppl). (abstr 7018).
29. Ni Chonghaile T., Sarosiek K.A., Vo T.T., Ryan J.A., Tammareddi A., Moore Vdel G., et al. Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy. Science 2011, 334:1129-1133.